Mostrando 2 resultados de: 2
Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine
ArticleAbstract: Purpose: Epidermal growth factor (EGF) might be a suitable immunotherapeutic target in non-small-celPalabras claves:Autores:Carmen Elena Viada, De La Torre A.V., García Verdecia B., González G., Lage Davila A., Leonard I., Martínez R., Mazorra Z., Neninger Vinageras E., Tania CrombetFuentes:scopusPhase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer
ArticleAbstract: Purpose: We show the result of a randomized phase II clinical trial with an epidermal growth factorPalabras claves:Autores:Abreu D.A., Bravo I., Brooks S.A., Carmen Elena Viada, Carrillo C.d.C., Dávila A.L., De La Torre A.V., Del Pino M.M., Dueñas M.G., Ferrer M.C., Marinello G.G., Ramos T.C., Rives R., Rodríguez M.O., Verdecia B.G., Vinageras E.N.Fuentes:scopus